X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (133276) 133276
Book Review (21933) 21933
Publication (6950) 6950
Conference Proceeding (301) 301
Book / eBook (189) 189
Book Chapter (102) 102
Magazine Article (96) 96
Newsletter (57) 57
Dissertation (38) 38
Transcript (36) 36
Newspaper Article (21) 21
Paper (7) 7
Data Set (6) 6
Trade Publication Article (4) 4
Web Resource (4) 4
Presentation (3) 3
Reference (3) 3
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (128990) 128990
index medicus (125970) 125970
antineoplastic combined chemotherapy protocols - therapeutic use (104053) 104053
female (81855) 81855
male (67546) 67546
middle aged (62751) 62751
oncology (61346) 61346
adult (52067) 52067
aged (51519) 51519
chemotherapy (38113) 38113
treatment outcome (32343) 32343
cancer (30542) 30542
combined modality therapy (26021) 26021
antineoplastic combined chemotherapy protocols - adverse effects (24217) 24217
prognosis (20791) 20791
neoplasm staging (18507) 18507
cisplatin - administration & dosage (17672) 17672
antineoplastic agents - therapeutic use (15377) 15377
aged, 80 and over (14896) 14896
hematology (14730) 14730
survival rate (14707) 14707
adolescent (14197) 14197
disease-free survival (13709) 13709
fluorouracil - administration & dosage (13622) 13622
retrospective studies (13537) 13537
care and treatment (13399) 13399
therapy (13147) 13147
animals (12877) 12877
breast neoplasms - drug therapy (12784) 12784
doxorubicin - administration & dosage (12571) 12571
antineoplastic combined chemotherapy protocols - administration & dosage (12376) 12376
cyclophosphamide - administration & dosage (12221) 12221
survival analysis (12040) 12040
follow-up studies (11993) 11993
lung neoplasms - drug therapy (11809) 11809
chemotherapy, adjuvant (11297) 11297
survival (11000) 11000
drug administration schedule (10981) 10981
cisplatin (10219) 10219
remission induction (10063) 10063
medicine & public health (9950) 9950
child (9801) 9801
abridged index medicus (9682) 9682
surgery (9084) 9084
radiotherapy (9053) 9053
carcinoma (8886) 8886
vincristine - administration & dosage (8742) 8742
research (8628) 8628
pharmacology & pharmacy (8367) 8367
analysis (7962) 7962
tumors (7954) 7954
trial (7747) 7747
breast cancer (7697) 7697
mice (7660) 7660
time factors (7386) 7386
cell line, tumor (7282) 7282
deoxycytidine - analogs & derivatives (7194) 7194
breast neoplasms - pathology (7175) 7175
etoposide - administration & dosage (7105) 7105
hematology, oncology and palliative medicine (7051) 7051
prospective studies (6932) 6932
child, preschool (6902) 6902
health aspects (6858) 6858
carcinoma, non-small-cell lung - drug therapy (6830) 6830
clinical trials as topic (6805) 6805
antineoplastic agents - administration & dosage (6749) 6749
antineoplastic agents (6718) 6718
dose-response relationship, drug (6685) 6685
metastasis (6609) 6609
paclitaxel - administration & dosage (6518) 6518
neoplasm metastasis (6498) 6498
adenocarcinoma - drug therapy (6456) 6456
young adult (6227) 6227
drug therapy (6221) 6221
antimitotic agents (5988) 5988
risk factors (5889) 5889
apoptosis (5850) 5850
deoxycytidine - administration & dosage (5765) 5765
carboplatin - administration & dosage (5748) 5748
antineoplastic agents - pharmacology (5733) 5733
methotrexate - administration & dosage (5698) 5698
neoplasms - drug therapy (5647) 5647
recurrence (5416) 5416
lung neoplasms - pathology (5351) 5351
paclitaxel (5316) 5316
neoadjuvant therapy (5287) 5287
disease progression (5152) 5152
colorectal neoplasms - drug therapy (5045) 5045
expression (5045) 5045
clinical trials (5024) 5024
combination (4991) 4991
prednisone - administration & dosage (4950) 4950
phase-ii (4893) 4893
antineoplastic agents - adverse effects (4876) 4876
doxorubicin (4874) 4874
ovarian neoplasms - drug therapy (4867) 4867
fluorouracil (4808) 4808
kaplan-meier estimate (4671) 4671
cyclophosphamide (4627) 4627
lymphatic metastasis (4582) 4582
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (143) 143
Collection Dvlpm't (Acquisitions) - Vendor file (11) 11
Collection Dvlpm't (Acquisitions) - Closed Orders (8) 8
Online Resources - Online (7) 7
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (5) 5
Chemistry (A D Allen) - Stacks (2) 2
Gerstein Science - Circulation Desk (2) 2
Credit Valley Hospital - Stacks (1) 1
St. Michael's Hospital - Stacks (1) 1
UTL at Downsview - May be requested (1) 1
West Park Healthcare Centre - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (115144) 115144
Japanese (8031) 8031
French (2339) 2339
German (2201) 2201
Chinese (1927) 1927
Russian (1164) 1164
Spanish (829) 829
Italian (566) 566
Polish (546) 546
Hungarian (258) 258
Dutch (135) 135
Czech (108) 108
Romanian (56) 56
Ukrainian (52) 52
Hebrew (49) 49
Danish (45) 45
Bulgarian (39) 39
Korean (37) 37
Serbian (33) 33
Portuguese (31) 31
Finnish (28) 28
Croatian (23) 23
Norwegian (21) 21
Swedish (15) 15
Slovak (12) 12
Lithuanian (8) 8
Turkish (7) 7
Bosnian (4) 4
Afrikaans (2) 2
Arabic (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA, ISSN 0098-7484, 06/2017, Volume 317, Issue 23, pp. 2392 - 2401
IMPORTANCE: Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic... 
MEDICINE, GENERAL & INTERNAL | LEUCOVORIN | FIRE-3 | THERAPY | FOLFIRI PLUS CETUXIMAB | PHASE-II | IRINOTECAN | OXALIPLATIN | FLUOROURACIL | TUMORS | PROGRESSION | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bevacizumab - therapeutic use | United States | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Cetuximab - therapeutic use | Cetuximab - adverse effects | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Canada | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - secondary | Aged | Genes, ras | Organoplatinum Compounds - adverse effects | Chemotherapy | Usage | Care and treatment | Research | Colorectal cancer | Cancer | Drugs | Medical research | Colorectal carcinoma | Clinical trials | Cytotoxicity | Patients | Survival | K-Ras protein | Bevacizumab | Metastases | Survival analysis | Irinotecan | Randomization | Oxaliplatin | Monoclonal antibodies | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
2009, Current clinical oncology, ISBN 9781603270861, xxviii, 637
A panel of international authorities analyzes in depth in this book the role of the lymphovascular system in the spread of cancer. They also summarize the... 
Neoplasms Invasiveness | Neoplasm Metastasis | Clinical & internal medicine | Metastasis | Lymphangiogenesis - drug effects | Pathology | Oncology | Medicine & Public Health | Radiotherapy | Surgical Oncology
Book
The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 19, pp. 1823 - 1833
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 22, pp. 2078 - 2092
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 13, pp. 1302 - 1308
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2013, Volume 368, Issue 2, pp. 138 - 148
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 23, pp. 2167 - 2177
The ALK inhibitor crizotinib as first-line therapy was associated with a significantly better response rate, longer progression-free survival, and greater... 
CRITERIA | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | CISPLATIN | ADENOCARCINOMA | PHASE-III | KINASE | ANAPLASTIC LYMPHOMA | QLQ-C30 | PLUS | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Cisplatin - administration & dosage | Pyridines - adverse effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carboplatin - administration & dosage | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Glutamates - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Guanine - administration & dosage | Appetite | Edema | Inhibitor drugs | Intravenous administration | Biomedical research | Lung | Lung cancer | Diarrhea | Fatigue | Nausea | Metastasis | Patients | Cisplatin | Quality of life | Chemotherapy | Platinum | Vomiting | Comparative studies | Carboplatin | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2015, Volume 373, Issue 1, pp. 23 - 34
Journal Article